Search Results

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today announced that it and its partner AnGes, Inc. received marketing approval from the Ministry of Health, Labour and Welfare for Zokinvy (lonafarnib), a treatment for Hutchinson-Gilford progeria syndrome (HGPS) and processing deficient progeroid laminopathy (PDPL).

Angany Inc., announces that it has received clearance (Notice of Acceptance) from MHRA (Medicines and Healthcare Products Regulatory Agency) for the first clinical study to be conducted on its vaccine candidate ANG-101 to treat human allergy to cats.

Vasomune Therapeutics and AnGes drug candidate AV-001 Receives Positive Recommendation from the IDSMB for AV001-004 Phase 2a Study.

Innovent Biologics, Inc. presents latest data of two ophthalmic bispecific antibodies at the American Academy of Ophthalmology 2023 Annual Meeting, including a Phase 2 clinical study of anti-VEGF and anti-complement bispecific fusion protein for neovascular age-related macular degeneration and a Phase 1 clinical study of anti-VEGF-A/Ang-2 bispecific antibody for diabetic macular edema.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented interim data from the ongoing Phase 2 GATEWAY clinical study of ARO-ANG3, the company’s investigational RNAi therapeutic designed to reduce expression of angiopoietin-like protein 3 (ANGPTL3), in patients with homozygous familial hypercholesterolemia (HoFH).

◆Investment to support services growth. ◆Industry veterans join board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.

Vasomune Therapeutics, Inc. has been selected by the American Thoracic Society to showcase its lead drug candidate AV-001 at the 2024 Respiratory Innovation Summit (RIS).

Eiger Biopharmaceuticals Inc. (“Eiger”, Nasdaq: EIGR) and AnGes Inc. (“AnGes”, TYO: 4563) today announced that the companies entered into an agreement for the regulatory approval, marketing, and distribution of Zokinvy® (lonafarnib) for the treatment of Hutchinson-Gilford progeria syndrome (HGPS or progeria) and processing-deficient progeroid laminopathies (PL) in Japan.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system